Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.

Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA.

Blood. 2003 Jun 15;101(12):4982-9. Epub 2003 Feb 27.

2.

Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia.

Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H.

Leuk Lymphoma. 2005 Mar;46(3):393-9.

PMID:
15621829
3.

Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival.

Wang Y, Fang M, Sun X, Sun J.

Int J Lab Hematol. 2010 Apr;32(2):230-8. doi: 10.1111/j.1751-553X.2009.01178.x. Epub 2009 Jul 15.

PMID:
19614710
4.

High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis.

Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ, Park C.

Lab Invest. 2008 Feb;88(2):144-52. Epub 2007 Dec 24.

5.

Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.

Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G.

Br J Haematol. 2003 Mar;120(6):953-9.

PMID:
12648064
6.

Telomere shortening in patients with plasma cell disorders.

Cottliar A, Pedrazzini E, Corrado C, Engelberger MI, Narbaitz M, Slavutsky I.

Eur J Haematol. 2003 Nov;71(5):334-40.

PMID:
14667196
7.

Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.

Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T, Thaler J.

Cancer Res. 1998 Nov 1;58(21):4918-22.

8.

Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity.

Spyridopoulos I, Hoffmann J, Aicher A, Brümmendorf TH, Doerr HW, Zeiher AM, Dimmeler S.

Circulation. 2009 Oct 6;120(14):1364-72. doi: 10.1161/CIRCULATIONAHA.109.854299. Epub 2009 Sep 21.

9.

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N.

Br J Haematol. 2005 Jan;128(2):210-7.

PMID:
15638855
10.

Clinical significance of telomerase activity in multiple myeloma.

Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H, Nishimura J.

Cancer. 2002 Apr 15;94(8):2232-8.

11.

Telomere length is a prognostic factor in neuroblastoma.

Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, Zaizov R, Yaniv I.

Cancer. 2006 Sep 15;107(6):1391-9.

12.

Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.

Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M.

Cancer. 2003 May 1;97(9):2212-7.

13.

Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma.

Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P.

Cancer. 2006 Feb 1;106(3):541-51.

14.

Telomerase activity in myelodysplastic syndromes.

Gürkan E, Tanriverdi K, Başlamişli F.

Leuk Res. 2005 Oct;29(10):1131-9. Epub 2005 Apr 7.

PMID:
16111531
15.

Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.

Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.

Eur J Haematol. 2004 Apr;72(4):252-8.

PMID:
15089762
16.

[Soluble syndecan-1 levels in different plasma cell dyscrasias].

Jánosi J, Sebestyén A, Mikala G, Petö M, Jákó J, Domján G, Németh J, Kis Z, Kopper L, Vályi-Nagy I.

Orv Hetil. 2005 Jan 23;146(4):165-8. Hungarian.

PMID:
15751511
17.

Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.

Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A.

Liver Int. 2009 Sep;29(8):1162-70. doi: 10.1111/j.1478-3231.2009.02082.x. Epub 2009 Jul 17.

PMID:
19627485
18.

Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.

Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H, Siewert JR.

J Clin Oncol. 2004 May 15;22(10):1807-14.

PMID:
15143073
19.

High heparanase activity in multiple myeloma is associated with elevated microvessel density.

Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD.

Cancer Res. 2003 Dec 15;63(24):8749-56.

20.

[Correlations of telomere length and telomerase activity to radiosensitivity of human laryngeal squamous carcinoma cells].

Xiao CY, Zhou FX, Liu SQ, Xie CH, Dai J, Zhou YF.

Ai Zheng. 2005 Jun;24(6):653-6. Chinese.

PMID:
15946472

Supplemental Content

Support Center